Breaking News, Collaborations & Alliances

Avista, Forge Enter Development & Manufacturing Partnership

Avista will leverage Forge’s FUEL platform to manufacture AAV for AVST-101, Avista’s lead gene therapy to treat patients with X-linked retinoschisis (XLRS).

By: Rachel Klemovitch

Assistant Editor

Avista Therapeutics (Avista), a pre-clinical-stage biotechnology company, and Forge Biologics, (Forge), a manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, entered a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate targeting X-linked retinoschisis (XLRS), a serious inherited retinal disease. AVST‑101 is a next-generation gene therapy designed to treat XLRS through a combination of advanc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters